Human T-cell leukemia virus type 1
Other Names for this Disease
- Human T lymphotropic virus type 1
retroviral infection that affect the T cells (a type of white blood cell). Although this virus generally causes no signs or symptoms, some affected people may later develop adult T-cell leukemia (ATL), HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) or other medical conditions. HTLV-1 is spread by blood transfusions, sexual contact and sharing needles. It can also be spread from mother to child during birth or breast-feeding. There is no cure or treatment for HTLV-1 and it is considered a lifelong condition; however, most (95%) infected people remain asymptomatic (show no symptoms) throughout life.Human T-cell leukemia virus, type 1 (HTLV-1) is a
Last updated: 12/10/2014
- David T Scadden, MD; Andrew R Freedman, FRCP; Paul Robertson, MRCP. Human T-lymphotropic virus type I: Virology, pathogenesis, and epidemiology. UpToDate. June 2014;
- HTLV Type I and Type II. NORD. May 2012; http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/1203/viewAbstract.
- Ewa Maria Szczypinska, MD. Human T-Cell Lymphotropic Viruses. Medscape. August 2014; http://emedicine.medscape.com/article/219285-overview.
- The National Cancer Institute provides the most current information on cancer for patients, health professionals, and the general public.
- The National Organization for Rare Disorders (NORD) has a report for patients and families about this condition. NORD is a patient advocacy organization for individuals with rare diseases and the organizations that serve them.
- Medscape Reference provides information on this topic. You may need to register to view the medical textbook, but registration is free.
- PubMed is a searchable database of medical literature and lists journal articles that discuss Human T-cell leukemia virus type 1. Click on the link to view a sample search on this topic.
- Oh U, Jacobson S. Treatment of HTLV-I-associated myelopathy/tropical spastic paraparesis: toward rational targeted therapy. Neurol Clin. 2008 Aug;26(3):781-97, ix-x.